Spinal FrontiersPowered by NSpineWeekly alert sign-up
← Back

Spinal Frontiers · Regulatory Watch · FDA decision

FDA Breakthrough Device Designation for antibiotic-releasing graft extender for lumbosacral fusion

FDA decision · Moroxite (Sweden)

17 November 2026

Moroxite announced FDA Breakthrough Device Designation for Xerafuse TOB, a resorbable graft-extending material that releases the antibiotic tobramycin, intended to extend bone graft in lumbosacral spinal fusion in patients at higher risk of infection. It is the company's second designation, after Xerafuse BMP in 2025. A designation gives closer contact with FDA and prioritised review; it is not a clearance or approval.

Type
FDA decision
Company
Moroxite (Sweden)
Device
Xerafuse TOB antibiotic-releasing bone graft extender
Date
17 November 2026
Jurisdiction
US
Classification
FDA Breakthrough Device Designation (not a clearance)
Source
Moroxite press release

Official source →Source checked

Other FDA decisions

← All of Regulatory Watch

Spinal Frontiers is published by NSpine Limited, registered in England and Wales (company no. 08362634), 14 Park Row, Nottingham NG1 6GR, United Kingdom. Every item is summarised in our own words and links to its original source. Listings are a selection made at NSpine's editorial discretion and are not exhaustive; inclusion is not an endorsement, and omission implies nothing. Sponsors and advertisers have no influence on what we cover. Nothing here is medical, legal or financial advice. Spotted an error or a broken link? Email spinalfrontiers@nspine.com, or use the feedback page.

Spinal Frontiers is a trademark of NSpine GmbH.

Information only, summarised from third-party sources: not medical, legal, regulatory or financial advice. Full disclaimer.

© 2013 – 2026 NSpine Limited. Privacy notice.